Ensuring AAV Characterization and Comparability Using Reliable AAV Reference Material
Gene therapy is transforming treatment paradigms, with AAV vectors at the forefront of clinical innovation. This webinar will highlight the critical need for robust AAV characterization and comparability, focusing on the use of high-quality, well-defined AAV reference materials.
Learn how these premium tools support accurate titer determination, capsid integrity analysis, and lot-to-lot consistency — key factors in regulatory submissions and therapeutic success. Join us to explore technical strategies that elevate AAV assay performance and standardization.
Speakers
Joshua Baal
Product Manager | PROGEN
Joshua Baal holds a Master in Molecular Cell Biology and has several years of hands-on industry experience. Before joining PROGEN as a Product Manager, he worked four years as an ecotoxicologist specializing in plant protection product registration. At PROGEN, Joshua oversees a broad portfolio of antibodies and related products, focusing on advancing gene therapy tools and standards.
Jacintha Victoria
Market Development Manager (CGT) | Refeyn
Jacintha Victoria is a strategic marketing and analytical leader with over a decade of experience in the biotechnology and gene therapy sectors. As Market Development Manager at Refeyn Ltd. in Oxford, UK, she leads initiatives to drive the adoption of Mass Photometry across cell and gene therapy applications, including AAV, LVV, adenovirus and RNA-based platforms. She holds a Master of Science in Cellular and Molecular Biology from the University of New Haven and is certified as a Technologist in Molecular Biology by the ASCP.
Key Learning Objectives
- Recognize the critical role of highly characterized AAV standards for accuracy, reproducibility and regulatory compliance in gene therapy analytics
- Understand the role of AAV standards in full/empty characterization
- Delve into the factors that influence the comparability of capsid titers between orthogonal methods
- Understand Mass Photometry as a single-molecule technique for directly measuring the mass of AAV viral vectors
- Compare Mass Photometry to orthogonal methods commonly used in the industry
- Explore how SamuxMP enables accurate characterization of heterogeneous AAV samples, supporting process monitoring and product quality control
Watch Now: Ensuring AAV Characterization and Comparability Using Reliable AAV Reference Material
This webinar is available on demand. Fill in the form to watch the full recording — we'll email you the link too.
- July 29, 2025 · 2:00 PM IST
- Joshua Baal, PROGEN
- kbiinfo@krishgen.com
- +91 22 49198700
Your details
Request the recording
Fill in your details and you'll go straight to the recording — we'll also email you the link.
More Webinars
Shortcuts to Discovery and Characterization of Monoclonal Antibodies
Monoclonal antibody (mAb) discovery and characterization often face significant delays due to iterative screening cycles, late-stage functional failures, and downstream analytical bottlenecks. This webinar details five practical shortcuts that accelerate timelines from target validation to preclinical characterization.
View Webinar June 12, 2026Viral Vectors & CRISPR for Building Disease Models
Gene editing and viral vector technologies are transforming the development of advanced disease models for translational research.
View Webinar April 17, 2026Advanced Immunocompetent Primary Human Airway Models for Respiratory Disease Modeling
Advancements in human-relevant in vitro models are transforming how respiratory diseases are studied and how drug safety and efficacy are evaluated.
View Webinar